Hector J Alonso Quiñones1,2, Bradley J Stish3, Clinton Hagen4, Ronald C Petersen4,5, Michelle M Mielke4,5. 1. School of Medicine, University of Puerto Rico, San Juan, Puerto Rico. 2. Mayo Clinic Alix School of Medicine and Center for Clinical and Translational Science. 3. Departments of Radiation Oncology. 4. Health Sciences Research. 5. Neurology, Mayo Clinic, Rochester, MN.
Abstract
INTRODUCTION: The association of prostate cancer and androgen deprivation therapy (ADT) use with the odds of developing mild cognitive impairment (MCI) was determined in men from the population-based Mayo Clinic Study of Aging (MCSA). METHODS: The study included 2513 men (mean age of 73.1 y) enrolled in the MCSA. A history of prostate cancer, ADT use, and length of ADT exposure before their first MCSA visit was abstracted using the Rochester Epidemiology Project medical records-linkage system. MCI was diagnosed at the baseline visit. Logistic regression was used to determine whether prostate cancer and ADT use was associated with odds of MCI. RESULTS: Of the 2513 participants, 349 (13.9%) had a history of prostate cancer; among whom 99 (28.3%) were treated with ADT before MCSA enrollment. There were 382 (15.2%) with a diagnosis of MCI. In the univariate logistic regression models, prostate cancer (odds ratio, 1.50; 95% confidence interval, 1.12-2.00), and ADT exposure (odds ratio, 1.57; 95% confidence interval, 0.96-2.58) were associated with higher odds of MCI. These associations were greatly attenuated and not significant in multivariable models. CONCLUSIONS: Neither a diagnosis of prostate cancer nor ADT use was associated with odds of MCI in this cross-sectional population-based study.
INTRODUCTION: The association of prostate cancer and androgen deprivation therapy (ADT) use with the odds of developing mild cognitive impairment (MCI) was determined in men from the population-based Mayo Clinic Study of Aging (MCSA). METHODS: The study included 2513 men (mean age of 73.1 y) enrolled in the MCSA. A history of prostate cancer, ADT use, and length of ADT exposure before their first MCSA visit was abstracted using the Rochester Epidemiology Project medical records-linkage system. MCI was diagnosed at the baseline visit. Logistic regression was used to determine whether prostate cancer and ADT use was associated with odds of MCI. RESULTS: Of the 2513 participants, 349 (13.9%) had a history of prostate cancer; among whom 99 (28.3%) were treated with ADT before MCSA enrollment. There were 382 (15.2%) with a diagnosis of MCI. In the univariate logistic regression models, prostate cancer (odds ratio, 1.50; 95% confidence interval, 1.12-2.00), and ADT exposure (odds ratio, 1.57; 95% confidence interval, 0.96-2.58) were associated with higher odds of MCI. These associations were greatly attenuated and not significant in multivariable models. CONCLUSIONS: Neither a diagnosis of prostate cancer nor ADT use was associated with odds of MCI in this cross-sectional population-based study.
Authors: Heather L McGinty; Kristin M Phillips; Heather S L Jim; Julie M Cessna; Yasmin Asvat; Mallory G Cases; Brent J Small; Paul B Jacobsen Journal: Support Care Cancer Date: 2014-05-25 Impact factor: 3.603
Authors: Shabbir M H Alibhai; Narhari Timilshina; Sarah Duff-Canning; Henriette Breunis; Ian F Tannock; Gary Naglie; Neil E Fleshner; Murray D Krahn; Padraig Warde; Shireen Marzouk; George A Tomlinson Journal: Cancer Date: 2016-09-01 Impact factor: 6.860
Authors: Rosebud O Roberts; Yonas E Geda; David S Knopman; Ruth H Cha; V Shane Pankratz; Bradley F Boeve; Robert J Ivnik; Eric G Tangalos; Ronald C Petersen; Walter A Rocca Journal: Neuroepidemiology Date: 2008-02-07 Impact factor: 3.282
Authors: C M Roe; A L Fitzpatrick; C Xiong; W Sieh; L Kuller; J P Miller; M M Williams; R Kopan; M I Behrens; J C Morris Journal: Neurology Date: 2009-12-23 Impact factor: 9.910
Authors: Kevin T Nead; Greg Gaskin; Cariad Chester; Samuel Swisher-McClure; Nicholas J Leeper; Nigam H Shah Journal: JAMA Oncol Date: 2017-01-01 Impact factor: 31.777
Authors: Jane A Driver; Alexa Beiser; Rhoda Au; Bernard E Kreger; Greta Lee Splansky; Tobias Kurth; Douglas P Kiel; Kun Ping Lu; Sudha Seshadri; Phillip A Wolf Journal: BMJ Date: 2012-03-12